This Plain Language Summary of Publication article (PLSP) from Future Oncology presents findings from the CHAPTER-GIST-301 phase 3 clinical trial, which evaluated pimitespib as a potential fourth-line treatment for advanced gastrointestinal stromal tumor (GIST). The study focused on patients whose cancer had progressed despite previous treatment with standard first-, second-, and third-line tyrosine kinase inhibitor therapies. Researchers compared pimitespib against a placebo to determine both its effectiveness in treating these rare digestive tract cancers and to document any side effects associated with the medication, providing valuable insights for patients who have exhausted conventional treatment options.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial’ and was published in Annals of Oncology. 

Visit Elsevier using the link to read the original article.